BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Wall Street Zen

BioCryst Pharmaceuticals (NASDAQ:BCRX) was upgraded by Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also issued reports about the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Citizens Jmp boosted their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Cantor Fitzgerald raised their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. Finally, Royal Bank Of Canada dropped their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Thursday. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $9.38 on Friday. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.22. The stock has a 50 day moving average price of $9.33 and a two-hundred day moving average price of $8.72. The stock has a market capitalization of $2.40 billion, a P/E ratio of -6.25 and a beta of 0.56.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. During the same quarter last year, the firm posted $0.15 earnings per share. The company’s quarterly revenue was up 33.6% compared to the same quarter last year. Sell-side analysts anticipate that BioCryst Pharmaceuticals will post -2.44 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. Royal Bank of Canada increased its stake in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 1,458 shares during the last quarter. Cetera Investment Advisers boosted its stake in shares of BioCryst Pharmaceuticals by 13.8% during the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after buying an additional 1,494 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of BioCryst Pharmaceuticals by 7.4% during the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after buying an additional 1,527 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 2,115 shares in the last quarter. Finally, Legato Capital Management LLC grew its holdings in shares of BioCryst Pharmaceuticals by 10.0% in the 4th quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company’s stock valued at $187,000 after acquiring an additional 2,172 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.